Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

por Leblond, Véronique, Aktan, Melih, Ferra Coll, Christelle M., Dartigeas, Caroline, Kisro, Jens, Montillo, Marco, Raposo, João, Merot, Jean-Louis, Robson, Susan, Gresko, Ekaterina, Bosch, Francesc, Stilgenbauer, Stephan, Foà, Robin
Publicado 2018

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

por Stilgenbauer, Stephan, Leblond, Veronique, Foà, Robin, Böttcher, Sebastian, Ilhan, Osman, Knauf, Wolfgang, Mikuskova, Eva, Renner, Christoph, Tausch, Eugen, Woszczyk, Dariusz, Gresko, Ekaterina, Lundberg, Linda, Moore, Tom, Morris, Thea, Robson, Susan, Bosch, Francesc
Publicado 2018

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

por Bosch, Francesc, Cantin, Guy, Cortelezzi, Agostino, Knauf, Wolfgang, Tiab, Mourad, Turgut, Mehmet, Zaritskey, Andrey, Merot, Jean-Louis, Tausch, Eugen, Trunzer, Kerstin, Robson, Susan, Gresko, Ekaterina, Böttcher, Sebastian, Foà, Robin, Stilgenbauer, Stephan, Leblond, Véronique
Publicado 2019